- Page 1 and 2:
A systematic review of the effectiv
- Page 3 and 4:
A systematic review of the effectiv
- Page 5 and 6:
Objectives: This report reviews the
- Page 7:
Glossary and list of abbreviations
- Page 10 and 11:
viii Glossary and list of abbreviat
- Page 13 and 14:
Background Rheumatoid arthritis (RA
- Page 15:
increased risk of serious infection
- Page 19 and 20:
Summary RA is a common, chronic, in
- Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
- Page 23 and 24:
Assessment of response to DMARDs Re
- Page 25 and 26:
combination with methotrexate or al
- Page 27:
disease between clinic appointments
- Page 30 and 31:
14 Effectiveness in juvenile arthri
- Page 32 and 33:
16 Effectiveness adalimumab plus me
- Page 34 and 35:
18 Effectiveness Monoclonal Antibod
- Page 36 and 37:
20 TABLE 1 Description of included
- Page 38 and 39:
22 TABLE 2 Quality of included RCTs
- Page 40 and 41:
24 Effectiveness change in modified
- Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
- Page 44 and 45:
28 Effectiveness Review: Adalimumab
- Page 46 and 47:
30 Effectiveness Review: Adalimumab
- Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
- Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
- Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
- Page 54 and 55:
38 Effectiveness etanercept trials.
- Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
- Page 58 and 59:
42 Effectiveness Review: Etanercept
- Page 60 and 61:
44 Effectiveness Review: Etanercept
- Page 62 and 63:
46 Effectiveness Review: Etanercept
- Page 64 and 65:
48 Effectiveness Review: Etanercept
- Page 66 and 67:
50 Effectiveness Review: Etanercept
- Page 68 and 69:
52 Effectiveness Review: Etanercept
- Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
- Page 72 and 73:
56 TABLE 12 Description of included
- Page 74 and 75:
58 TABLE 13 Quality of included RCT
- Page 76 and 77:
60 Effectiveness per week and escal
- Page 78 and 79:
62 Effectiveness significant advant
- Page 80 and 81:
64 Effectiveness Review: Infliximab
- Page 82 and 83:
66 Effectiveness Review: Infliximab
- Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
- Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
- Page 89 and 90:
Summary of review of existing econo
- Page 91 and 92:
TABLE 20 Summary of published ICERs
- Page 93 and 94:
TABLE 21 Published etanercept econo
- Page 95 and 96:
TABLE 23 Published economic analyse
- Page 97 and 98:
TABLE 25 Treatment sequences: adali
- Page 99 and 100:
management of RA, i.e. 1st and 2nd
- Page 101 and 102:
To estimate the long-term consequen
- Page 103 and 104:
TABLE 32 TNF inhibitors as last act
- Page 105 and 106:
TABLE 34 Basic structure of the mod
- Page 107 and 108:
een quit on grounds of toxicity, ad
- Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
- Page 111 and 112:
TABLE 43 Beta distributions for HAQ
- Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
- Page 115 and 116:
TABLE 46 Unit costs for tests and v
- Page 117 and 118:
following properties, according to
- Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
- Page 121 and 122:
TABLE 54 Base case: TNF inhibitors
- Page 123 and 124:
TABLE 59 Third TNF inhibitor follow
- Page 125 and 126:
TABLE 65 Sensitivity analyses: TNF
- Page 127 and 128:
TABLE 67 Sensitivity analyses: TNF
- Page 129:
The substantial economic impact of
- Page 133 and 134:
Summary Effectiveness: principal fi
- Page 135 and 136:
inhibitors, although the incrementa
- Page 137 and 138:
introduce bias which generally exag
- Page 139: Adalimumab, etanercept and inflixim
- Page 143 and 144: 1. Jobanputra P, Barton P, Bryan S,
- Page 145 and 146: 46. Young A, Dixey J, Cox N, Davies
- Page 147 and 148: tumor necrosis factor therapy in th
- Page 149 and 150: arthritis: a 12-week, double-blind,
- Page 151 and 152: 171. Geborek P, Crnkic M, Petersson
- Page 153 and 154: 216. Schotte H, Willeke P, Mickholz
- Page 155 and 156: The Health Assessment Questionnaire
- Page 157 and 158: Cochrane Library (CENTRAL) 2005 Iss
- Page 159 and 160: Appendix 3 © Queen’s Printer and
- Page 161: TABLE 69 Studies excluded from clin
- Page 164 and 165: 148 Appendix 4 TABLE 71 Meta-analys
- Page 166 and 167: 150 Appendix 4 TABLE 73 Meta-analys
- Page 168 and 169: 152 Appendix 4 Infliximab versus pl
- Page 170 and 171: 154 Appendix 4 Infliximab plus MTX
- Page 173: Ovid MEDLINE(R) 1966 to February we
- Page 177 and 178: Appendix 8 © Queen’s Printer and
- Page 179 and 180: TABLE 79 Wong et al., 2002 161 © Q
- Page 181 and 182: TABLE 80 Kobelt et al., 2003 162 (c
- Page 183 and 184: TABLE 82 Brennan et al., 2004 160
- Page 185 and 186: TABLE 83 Kobelt et al., 2004 163 (c
- Page 187 and 188: TABLE 85 Bansback et al., 2005 166
- Page 189: TABLE 86 Kobelt et al., 2005 167 (c
- Page 193: TABLE 92 Strategy set: infliximab a
- Page 196 and 197: 180 Appendix 10 TABLE 95 Variation
- Page 198 and 199: 182 Appendix 10 Variation 2 For thi
- Page 200 and 201: 184 Appendix 10 TABLE 101 Variation
- Page 202 and 203: 186 Appendix 10 TABLE 104 Variation
- Page 204 and 205: 188 Appendix 10 TABLE 107 Variation
- Page 206 and 207: 190 Appendix 10 Variation 5 For thi
- Page 208 and 209: 192 Appendix 10 TABLE 113 Variation
- Page 210 and 211: 194 Appendix 10 TABLE 116 Variation
- Page 212 and 213: 196 Appendix 10 TABLE 119 Variation
- Page 214 and 215: 198 Appendix 10 Variation 8 For thi
- Page 216 and 217: 200 Appendix 10 TABLE 125 Variation
- Page 218 and 219: 202 Appendix 10 TABLE 128 Variation
- Page 220 and 221: 204 Appendix 10 TABLE 131 Variation
- Page 222 and 223: 206 Appendix 10 Variation 11 In thi
- Page 224 and 225: 208 Appendix 10 TABLE 137 Variation
- Page 226 and 227: 210 Appendix 10 TABLE 140 Variation
- Page 228 and 229: 212 Appendix 10 TABLE 143 Variation
- Page 230 and 231: 214 Appendix 10 Variation 14 In thi
- Page 232 and 233: 216 Appendix 10 TABLE 149 Variation
- Page 234 and 235: 218 Appendix 10 TABLE 152 Variation
- Page 236 and 237: 220 Appendix 10 TABLE 155 Variation
- Page 238 and 239: 222 Appendix 10 Variation 17 In thi
- Page 240 and 241:
224 Appendix 10 TABLE 161 Variation
- Page 242 and 243:
226 Appendix 10 TABLE 164 Variation
- Page 245:
Additional ongoing/unpublished tria
- Page 248 and 249:
232 Health Technology Assessment re
- Page 250 and 251:
234 Health Technology Assessment re
- Page 252 and 253:
236 Health Technology Assessment re
- Page 254 and 255:
238 Health Technology Assessment re
- Page 256 and 257:
240 Health Technology Assessment re
- Page 258 and 259:
242 Health Technology Assessment re
- Page 261 and 262:
Members Chair, Professor Tom Walley
- Page 263 and 264:
Members Chair, Professor Bruce Camp
- Page 266:
Feedback The HTA Programme and the